307 related articles for article (PubMed ID: 27559828)
1. Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.
Carlino L; Rastelli G
J Med Chem; 2016 Oct; 59(20):9305-9320. PubMed ID: 27559828
[TBL] [Abstract][Full Text] [Related]
2. Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development.
Hameed R; Khan A; Khan S; Perveen S
Anticancer Agents Med Chem; 2019; 19(5):592-598. PubMed ID: 30306880
[TBL] [Abstract][Full Text] [Related]
3. Promising Targets in Anti-cancer Drug Development: Recent Updates.
Kumar B; Singh S; Skvortsova I; Kumar V
Curr Med Chem; 2017; 24(42):4729-4752. PubMed ID: 28393696
[TBL] [Abstract][Full Text] [Related]
4. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
5. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
6. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
Verkhivker GM
Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
[TBL] [Abstract][Full Text] [Related]
7. Small molecule kinase inhibitors as anti-cancer therapeutics.
Chahrour O; Cairns D; Omran Z
Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944
[TBL] [Abstract][Full Text] [Related]
8. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic protein kinase inhibitors.
Grant SK
Cell Mol Life Sci; 2009 Apr; 66(7):1163-77. PubMed ID: 19011754
[TBL] [Abstract][Full Text] [Related]
10. Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.
Allen BK; Mehta S; Ember SW; Schonbrunn E; Ayad N; Schürer SC
Sci Rep; 2015 Nov; 5():16924. PubMed ID: 26596901
[TBL] [Abstract][Full Text] [Related]
11. Coumarins as anticancer agents: a review on synthetic strategies, mechanism of action and SAR studies.
Thakur A; Singla R; Jaitak V
Eur J Med Chem; 2015 Aug; 101():476-95. PubMed ID: 26188907
[TBL] [Abstract][Full Text] [Related]
12. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.
Verkhivker GM
Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654
[TBL] [Abstract][Full Text] [Related]
13. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.
Hantschel O
ACS Chem Biol; 2015 Jan; 10(1):234-45. PubMed ID: 25531586
[TBL] [Abstract][Full Text] [Related]
14. Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment.
Ceramella J; Iacopetta D; Barbarossa A; Caruso A; Grande F; Bonomo MG; Mariconda A; Longo P; Carmela S; Sinicropi MS
Mini Rev Med Chem; 2020; 20(6):444-465. PubMed ID: 31951166
[TBL] [Abstract][Full Text] [Related]
15. Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors.
Kulkarni MR; Mane MS; Ghosh U; Sharma R; Lad NP; Srivastava A; Kulkarni-Almeida A; Kharkar PS; Khedkar VM; Pandit SS
Eur J Med Chem; 2017 Jul; 134():366-378. PubMed ID: 28431342
[TBL] [Abstract][Full Text] [Related]
16. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Shallal HM; Russu WA
Eur J Med Chem; 2011 Jun; 46(6):2043-57. PubMed ID: 21429632
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents.
Guo T; Ma S
ChemMedChem; 2021 Feb; 16(4):600-620. PubMed ID: 33179854
[TBL] [Abstract][Full Text] [Related]
18. Binding patterns and structure-activity relationship of CDK8 inhibitors.
Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
[TBL] [Abstract][Full Text] [Related]
19. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.
Marak BN; Dowarah J; Khiangte L; Singh VP
Eur J Med Chem; 2020 Oct; 203():112571. PubMed ID: 32707525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]